SHARE THIS ARTICLE
Hymovis
Hymovis vs Euflexxa – Which is Better for OA?
Nov 20, 2024
Osteoarthritis (OA) is a common joint disorder affecting millions worldwide. According to a comprehensive review, OA is the most prevalent form of arthritis in the United States, impacting 22.7% of the adult population. The knee is the most commonly affected joint, with up to 41% of OA cases involving this area.
Two popular treatments for knee OA are Hymovis and Euflexxa. Both are hyaluronic acid injections designed to alleviate pain and improve joint function. Hymovis and Euflexxa have shown varying degrees of effectiveness in clinical studies, making it important to compare their benefits and drawbacks.
In this article, we will compare Hymovis vs Euflexxa, examining their effectiveness, treatment regimens, and potential side effects to determine which may be more suitable for managing osteoarthritis symptoms.
Key Takeaways
- Hymovis uses a thicker, highly viscoelastic hyaluronic acid requiring just two injections, while Euflexxa mimics natural joint fluid in a three-injection series.
- Both treatments effectively improve knee mobility and reduce osteoarthritis pain, with Hymovis offering results lasting up to a year and Euflexxa lasting around six months.
- Both are FDA-approved and have established safety profiles. They have mild side effects, such as swelling or discomfort at the injection site.
- Hymovis is preferred for convenience, while Euflexxa appeals to those who favor a gradual improvement through a traditional schedule.
About: Trusted by over 2,000+ global clients since 2014, Direct Doctor Supply has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Direct Doctor Supply offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world.
Understanding Hymovis vs Euflexxa
Hymovis and Euflexxa are injectable viscosupplements designed to relieve knee pain caused by osteoarthritis. They differ in formulation, mechanism of action, and treatment schedules. Hymovis features a unique, highly viscoelastic hyaluronic acid that provides prolonged joint lubrication and cushioning. Its thicker consistency requires only two injections, spaced one week apart, making it a convenient option.

On the other hand, Euflexxa mimics the natural viscosity of synovial fluid to improve joint function.[1] Administered as a series of three weekly injections, it gradually enhances lubrication and reduces friction in the knee joint. Both treatments aim to restore joint mobility and alleviate pain by replenishing hyaluronic acid levels depleted by osteoarthritis.
While Hymovis offers a shorter treatment schedule, Euflexxa follows a multi-injection regimen that may suit patients who prefer a more traditional viscosupplementation approach. Both are FDA-approved hyaluronic acid treatments for knee osteoarthritis. Medical practitioners, clinics, and eligible buyers can order Hymovis wholesale or individually through Direct Doctor Supply, an online supplier of medical and orthopedic products.
Efficacy Comparison
For pain relief and joint lubrication, both Hymovis and Euflexxa have shown promising results in clinical studies. Hymovis has been found to significantly improve knee function and reduce pain in patients with osteoarthritis. A study showed that patients experienced improved knee function and reduced pain for up to 360 days after a single injection.[2]
Euflexxa has also demonstrated robust pain relief in multiple clinical trials. A 12-week study found it to be non-inferior to Synvisc, another popular viscosupplement, in reducing pain. In another trial, Euflexxa also provided significant pain relief for up to 26 weeks.
The duration and degree of symptom relief can vary by patient and treatment approach. Evidence such as this can provide useful context when evaluating viscosupplementation options, including Hymovis vs Euflexxa.
Safety Profiles and Patient Satisfaction
Hymovis and Euflexxa have established safety profiles and are FDA-approved for treating knee osteoarthritis. Hymovis FDA approval ensures its use as a reliable viscosupplement with minimal risk of adverse effects.

Common side effects for both treatments include mild pain, swelling, or stiffness at the injection site, which typically resolve within a few days. Serious complications, such as infections or allergic reactions, are extremely rare when a qualified professional administers the treatment.

Patient satisfaction with both treatments is generally high, with many reporting significant reductions in pain and improved mobility. Hymovis’s two-injection regimen is especially appreciated for its convenience, while Euflexxa’s gradual three-injection protocol appeals to those who prefer a slower, steady improvement.
On Hymovis
- biz…: “I love it! I was getting another injection every six months. Hymovis has been working very well for me. Now I get Hymovis every 12 months.”
On Euflexxa
- San…: “Started Euflexxa over 5 years ago for bone-on-bone in both knees. I have a series of three weekly injections twice a year. I walk every day and do Zumba twice a week. I have absolutely no pain with the injections (my doctor knows what he is doing) and have been relatively pain-free. I am a 73-year-old female.”
Choosing the Right Treatment for OA
Selecting an appropriate viscosupplement for knee osteoarthritis (OA) involves considering the patient’s individual needs and the characteristics of each treatment. When reviewing options such as Hymovis vs Euflexxa, practitioners can consider factors including treatment goals, medical history, symptom severity, previous treatment response, and preferred injection schedule.
Hymovis is ideal for patients seeking a convenient two-injection regimen with a thicker hyaluronic acid formulation for extended relief. In contrast, Euflexxa offers a three-injection schedule that mimics the natural viscosity of the joint fluid, providing a steady improvement over time. For patients who prioritize fewer visits, Hymovis may be more suitable, while those who prefer gradual symptom relief might opt for Euflexxa.
Additional considerations include each treatment’s duration of effectiveness. Practitioners can ensure optimal outcomes and satisfaction by aligning treatment choices with the patient’s goals—whether for pain relief, improved mobility, or both.
Conclusion
Hymovis and Euflexxa represent two excellent options for managing knee osteoarthritis through viscosupplementation. Hymovis stands out for its convenient two-injection regimen and longer-lasting effects, making it ideal for patients seeking fewer visits and extended relief. Euflexxa, with its three-injection protocol, offers a gradual but steady improvement in joint function and pain relief, mimicking the natural viscosity of joint fluid.
Both treatments have proven effective and safe in clinical studies. The choice largely depends on individual preferences, treatment goals, and lifestyle needs. Consulting with a healthcare provider is key to selecting the best option for managing osteoarthritis.
FAQs
1. How long does relief from Hymovis last?
Hymovis has been shown to relieve pain and improve joint function for up to one year in some patients.
2. Who is a good candidate for Hymovis?
Hymovis is ideal for patients with knee osteoarthritis who have not found relief from other conservative treatments like physical therapy or oral pain medications.
3. How does Hymovis compare to Euflexxa?
Hymovis offers a two-injection regimen with longer-lasting results, while Euflexxa requires three injections and provides steady, gradual relief. Both are effective but cater to different patient preferences.
Citations
Faryna, Alice, and Kim Goldenberg. “Joint Fluid.” PubMed, edited by H. Kenneth Walker et al., 3rd ed., Butterworths, 1990, https://www.ncbi.nlm.nih.gov/books/NBK274/. Accessed 25 Sept. 2026.
Bernetti, Andrea, et al. “New Viscoelastic Hydrogel Hymovis MO.RE. Single Intra-Articular Injection for the Treatment of Knee Osteoarthritis in Sportsmen: Safety and Efficacy Study Results.” Frontiers in Pharmacology, vol. 12, Frontiers Media SA, May 2021, https://doi.org/10.3389/fphar.2021.673988.
Peck J, Slovek A, Miro P, et al. A comprehensive review of viscosupplementation in osteoarthritis of the knee. Orthopedic Reviews. 2021;13(2). doi:10.52965/001c.25549
Comparative Study of Two Hyaluronic Acid Formulation in the Management of Knee Osteoarthritis. Ichgcp.net. Published May 8, 2024. Accessed November 20, 2024. https://ichgcp.net/clinical-trials-registry/NCT06528600
Sourcing and accuracy for this article follow our Editorial policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published

